A Phase 2b, Open-Label, Long-Term Extension Study to Evaluate the Safety and Pharmacodynamics of KRN23 in Adult Subjects with X-Linked Hypophosphatemia (XLH)

Administered By

Awarded By

Contributors

Start/End

  • March 15, 2015 - November 30, 2019